Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors

Bone Marrow Transplantation

Volumn 22, Issue 1, 1998, Pages 7-12

  Hara, J ^a,b   Osugi, Y ^a   Ohta, H ^a   Matsuda, Y ^a   Nakanishi, K ^a   Takai, K ^a   Fujisaki, H ^a   Tokimasa, S ^a   Fukuzawa, M ^a   Okada, A ^a   Okada, S ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b Suita City Hospital   (Japan)

Author keywords

Busulfan; High dose chemotherapy; Melphalan; Stem cell; Thiotepa

Indexed keywords

BUSULFAN; MELPHALAN; THIOTEPA;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; HEPATOBLASTOMA; HUMAN; MAXIMUM PERMISSIBLE DOSE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROBLASTOMA; NEUROTOXICITY; PNEUMONIA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SOLID TUMOR; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0031824152     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701283     Document Type: Article

References (23)

1. Graham-Pole J. Myeloablative treatment supported by marrow infusions for children with neuroblastoma. In: Armitage JO and Antman KH (eds). High-Dose Cancer Therapy. Williams and Wilkins: Baltimore, 1992, pp 735-749.
2. Frei III E. Pharmacologic strategies for high-dose chemotherapy. In: Armitage JO and Antman KH (eds). High-dose Cancer Therapy. Williams and Wilkins: Baltimore, 1992, pp3-13.
3. Eder JP, Elias A, Shea TC et al. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 1990; 8: 1239-1245.
4. Kalifa C, Hartmann O, Demeocq F et al. High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study. Bone Marrow Transplant 1992; 9: 227-233.
5. Weaver CH, Bensinger WI, Appelbaum FR et al. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 1994; 14: 813-819.
6. Wollf SN, Herzig RH, Fay JW et al. High-dose N,N',N"-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies. Semin Oncol 1990; 17 (Suppl. 3): 2-6.
7. Antman K, Eder JP, Elias A et al. High-dose thiotepa alone and in combination regimens with bone marrow support. Semin Oncol 1990; 17 (Suppl. 3): 33-38.
8. Matsuda Y, Hara J, Osugi Y et al. Allogeneic peripheral stem cell transplantation using positively selected CD34+ cells from HLA-mismatched donors. Bone Marrow Transplant 1998; 21: 355-360.
9. Stram DO, Matthay KK, O'Leary M et al. Consolidation chemoradiotherapy and autologous bone marrow transplantation vs continued chemotherapy for metastatic neuroblastoma: a report of two concurrent children's cancer group studies. J Clin Oncol 1996; 14: 2417-2426.
10. Hartmann O, Benhamou E, Beaujean F et al. High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a phase IT study. J Clin Oncol 1986; 4: 1804-1810.
11. Schiffman KS, Bensinger WI, Appelbaum FR et al. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplant 1996; 17: 943-950.
12. Ghalie R, Reynolds J, Valentino LA et al. Busulfan-containing pre-transplant regimens for the treatment of solid tumors. Bone Marrow Transplant 1994; 14: 437-442.
13. Kamani N, August CS, Bunin N et al. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma. Bone Marrow Transplant 1996; 17: 911-916.
14. Saarinen UM, Hovi L, Makipernaa A, Riikonen P. High-dose thiotepa with autologous bone marrow rescue in pediatric solid tumors. Bone Marrow Transplant 1991; 8: 369-376.
15. Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994; 14: 495-504.
16. Bitran JD, Williams SF, Moormeier J, Mick R. High-dose combination chemotherapy with thiotepa and autologous hematopoietic stem cell reinfusion in the treatment of patients with relapsed refractory lymphomas. Semin Oncol 1990; 17 (Suppl. 3): 39-12.
17. Williams SF, Bitran JD, Kaminer L et al. A phase I-II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer. J Clin Oncol 1987; 5: 260-265.
18. Kushner BH, O'Reilly RJ, Mandell LR et al. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol 1991; 9: 274-279.
19. Finlay JL, Goldman S, Wong MC et al. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. J Clin Oncol 1996; 14: 2495-2503.
20. Jagannath S, Barlogie B, Dicke K et al. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood 1990; 76: 1860-1866.
21. Emminger W, Emminger-Schmidmeier W, Hawliczek R et al. High-dose melphalan, etoposide ± carboplatin (MEC) combined with 12-gray fractionated total-body irradiation in children with generalized solid tumors. Pediatr Hematol Oncol 1991; 8: 13-22.
22. Burdach ST, Jurgens H, Peters C et al. Myeloablative radio-chemotherapy and hematopoietic stem rescue in poor prognosis Ewing sarcoma. J Clin Oncol 1993; 11: 1482-1488.
23. Koscielniak E, Klingebiel TH, Peters C et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian pediatric bone marrow transplantation group. Bore Marrow Transplant 1997; 19: 227-231.